Group members

Ligal joined our group in May 2019 after completing her B.Sc. in Biotechnology at the Faculty of Life Sciences, Tel Aviv University.

In her PhD project Ligal characterized the phenotype of tumor-infiltrating B lymphocytes, tumor-associated B cells and their distinct antibody repertoire.

During her B.Sc. she gained experience as a research assistant in our lab, working on the production, purification and validation of the Tetanus Toxoid C fragment (rTTC), and the purification of rTTC- and TT-specific antibodies from pregnant women.

Shira joined our group in October 2023 after completing her B.Sc. in Biology at the Faculty of Life Sciences, Tel Aviv University.

Her research focused on isolating and characterizing tumor-specific antibodies from the tumor microenvironment, with particular emphasis on patients with non-small cell lung cancer (NSCLC).

The project aimed to identify antibodies that could play a role in targeted cancer therapies by harnessing the body’s natural immune response.

Noam joined our group in October 2023 after completing her B.Sc. in Biology at the Faculty of Life Sciences, Tel Aviv University.

Her research focused on antibacterial antibody engineering.

Neta joined our group in October 2024 after completing her B.Sc. in Biotechnology and Biology at the Faculty of Life Sciences, Tel Aviv University.

Bar joined our group in October 2022 after completing his B.Sc. in Biology at the Faculty of Life Sciences, Tel Aviv University.

He completed his M.Sc. in Computational Biology. His research project focused on studying paratope–epitope interactions in antibodies.

Camilla joined our group in October 2021 after completing her B.Sc. in Biology at the Faculty of Life Sciences, Sapienza University of Rome.

In her M.Sc. Camilla worked on the dynamics of the vaccine-specific antibody response and the mother–baby interface.

Shai joined our group in October 2015 after completing her B.Sc. at the Faculty of Life Sciences, Tel Aviv University.

During her B.Sc. studies she worked as a research assistant in the Department of Zoology and in the Department of Molecular Microbiology and Biotechnology.

In her M.Sc. project Shai focused on the characterization of the antibodies elicited following infusion of an anti-TNFα agent (Infliximab) to IBD patients, looking for associations between neutralizing anti-drug antibodies and various cytokines (e.g. BAFF).

Limor joined our group in April 2016 after completing her master's thesis at the Department of Molecular Microbiology and Biotechnology, Tel Aviv University.

During her PhD, Limor focused on the impact of pregnancy on the nature of the immune response following maternal immunization.

In her M.Sc. studies, she developed an ex vivo system for high-throughput analysis of molecular chaperones as a therapeutic strategy for Von Hippel–Lindau syndrome.

Alongside her PhD research, Limor tutored future scientists in the ‘Tel Aviv University for Youth’ program, which encourages middle and high school students to discover and research in academia.

Tsuf joined the Wine lab in October 2019 after completing his B.Sc. in Life Sciences at the Faculty of Life Sciences, Ben-Gurion University.

Tsuf focused his research on the longitudinal kinetics of the serological response in COVID-19 recovered patients over a period of 14 months, comparing the longitudinal kinetics of recovered patients, naïve BNT162b2 vaccinees and recovered patients post vaccination.

Anna joined our group in October 2014 after completing her M.Sc. thesis at the Department of Molecular Microbiology and Biotechnology.

In her PhD project Anna analyzed the drug–antibody repertoire in inflammatory bowel disease patients treated with Infliximab.

During her M.Sc. she worked on developing an animal model for in vivo restoration of p53 cancer-associated mutations and a novel method of examining p53 DNA binding.

Yaron completed his PhD at Tel Aviv University, at the Department of Cell and Developmental Biology, Sackler Faculty of Medicine, under the supervision of Prof. Zvi Fishelson.

Yaron worked on a novel therapeutic monoclonal antibody to combat multidrug-resistant (MDR) pathogenic bacteria.

In his PhD he studied and characterized microRNAs that modulate the sensitivity of cancer cells to complement-dependent cytotoxicity.

Dan joined our group in October 2017 after completing his B.Sc. in Marine Biotechnology at the Ruppin Academic Center.

During his B.Sc. Dan participated in a research project under the supervision of Dr. Nir Nesher and Dr. Tal Shomrat, which focused on the structure and antibacterial activity of Octopus vulgaris skin mucus. His M.Sc. involved the study of antibacterial immunotherapy.